Galectin Therapeutics (GALT) Income towards Parent Company (2010 - 2026)

Galectin Therapeutics' Income towards Parent Company history runs 17 years deep, the most recent figure standing at -$6.0 million for Q1 2026.

• On a quarterly basis, Income towards Parent Company rose 37.24% year-over-year to -$6.0 million in Q1 2026; TTM through Mar 2026 was -$23.7 million, a 42.28% increase from a year earlier, with the FY2025 full-year figure at -$115.6 million, up 12.69% from the prior year.
• Income towards Parent Company eased to -$6.0 million in Q1 2026 per GALT's latest filing, from -$5.3 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at -$5.3 million in Q4 2025 and bottomed at -$12.5 million in Q2 2024.
• The 5-year median for Income towards Parent Company is -$9.9 million (2022), against an average of -$9.3 million.
• Across the five-year window, Income towards Parent Company sank 59.76% in 2022 and surged 48.52% in 2025, its largest moves.
• Year by year, Income towards Parent Company stood at -$11.5 million in 2022, then fell by 5.56% to -$12.1 million in 2023, then rose by 29.66% to -$8.5 million in 2024, then jumped by 38.11% to -$5.3 million in 2025, then dropped by 14.21% to -$6.0 million in 2026.
• Per Business Quant, the three latest GALT Income towards Parent Company figures stand at -$6.0 million (Q1 2026), -$5.3 million (Q4 2025), and -$6.0 million (Q3 2025).